For Research Use Only

FITC Anti-Human PD-1/CD279 (EH12.2H7)

Catalog Number: FITC-65168



Basic Information

Catalog Number:

FITC-65168

100 tests , 5 μ l/test

Source: Mouse Isotype:

IgG1, kappa

GenBank Accession Number:

BC074740 GeneID (NCBI):

UNIPROT ID: Q15116 Full Name:

programmed cell death 1

Calculated MW:

288 aa, 32 kDa

Purification Method:

The purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions. The conjugate is purified by sizeexclusion chromatography.

CloneNo.:

FH12.2H7

Recommended Dilutions: FC: 5 ul per 10^6 cells in 100 μ l

suspension

Excitation/Emission maxima

wavelengths: 498 nm / 526 nm

Applications

Tested Applications:

Species Specificity:

Non-human primates, Human

Positive Controls:

FC: PHA treated human PBMCs.

Background Information


Programmed cell death 1 (PD-1, also known as CD279) is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 subfamily of the Ig superfamily. It is a 288 amino acid (aa) type I transmembrane protein composed of one Ig superfamily domain, a stalk, a transmembrane domain, and an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based switch motif (ITSM) (PMID: 18173375). PD-1 is expressed during thymic development and is induced in a variety of hematopoietic cells in the periphery by antigen receptor signaling and cytokines (PMID: 20636820). Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function (PMID: 19426218). It is critical for the regulation of T cell function during immunity and tolerance. Blockade of PD-1 can overcome immune resistance and also has been shown to have antitumor activity (PMID: 22658127; 23169436).

Storage


Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

PBS with 0.09% sodium azide and 0.5% BSA, pH7.3

Selected Validation Data



1X10^6 PHA treated (3d) human PBMCs were surface stained with CL750 Anti-Human CD3 and 5 ul FITC Anti-Human CD279 (FITC-65168, Clone:EH12.2H7) (right) or Mouse IgG1 Isotype Control (left). 1X10^6 untreated human PBMCs were surface stained with CL750 Anti-Human CD3 and 5 ul FITC Anti-Human CD279 (FITC-65168, Clone:EH12.2H7) (center) Cells were not fixed.



FITC-65168 CD279 (EH12.2H7)

1X10^6 PHA treated (3d) human PBMCs were surface stained with 5 ul FITC Anti-Human CD279 (FITC-65168, Clone:EH12.2H7) (red) or Mouse IgG1 Isotype Control (blue). 1X10^6 untreated human PBMCs were surface stained with 5 ul FITC Anti-Human CD279 (FITC-65168, Clone:EH12.2H7) (black dashed) Cells were not fixed.